{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-25-000065","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.266705+00:00","generated_at":"2026-05-17T14:50:14.225998+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"AEON Biopharma reports Q2 2025 cash of $8.4M; advancing ABP-450 biosimilar milestones","bullets":["Cash and equivalents $8.4M as of June 30, 2025; expected to fund operations through Q4 2025 and Type 2a FDA meeting.","Primary structure and select functional analyses for ABP-450 expected to complete in Q3 2025.","Type 2a meeting with FDA on 351(k) biosimilar pathway anticipated in Q4 2025.","Pursuing ABP-450 as BOTOX biosimilar for all therapeutic indications; over $3B U.S. therapeutic market opportunity noted."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-25-000065","json":"https://secwatch.observer/filing/0001837607-25-000065.json","markdown":"https://secwatch.observer/filing/0001837607-25-000065.md","text":"https://secwatch.observer/filing/0001837607-25-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000065/0001837607-25-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000065/aeon-20250812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:50:14.225998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}